Bruce Eaton - May 9, 2023 Form 4 Insider Report for Editas Medicine, Inc. (EDIT)

Signature
/s/ Damien Grierson, Attorney-in-Fact
Stock symbol
EDIT
Transactions as of
May 9, 2023
Transactions value $
-$1,284
Form type
4
Date filed
5/11/2023, 04:30 PM
Previous filing
Mar 6, 2023
Next filing
May 15, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EDIT Common Stock Sale -$1.28K -135 -0.17% $9.51 77.4K May 9, 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on June 15, 2019, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on May 6, 2023. The sale does not represent a discretionary trade by the Reporting Person.
F2 This transaction was executed in multiple trades at prices ranging from $9.5100 to $9.5150.The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.